Literature DB >> 20721757

Extreme condition, extreme measures? Compliance, drug resistance, and the control of tuberculosis.

Ian Harper1.   

Abstract

This paper explores the issue of compliance by focusing on the control of tuberculosis. In the last ten years, patient compliance in tuberculosis control has discursively shifted from 'direct observation' of therapy to more patient-centred focus and support drawing on rights-based approaches in dealing with health care provision. At the same time, there has been an increased international concern with the rise of drug resistant forms of tuberculosis, and how to manage this. This paper looks at these issues and the tensions between them, by discussing the shift in discourses around the two and how they relate. Drawing on experience from work in Nepal, and its successful tuberculosis control programme, it looks at debates around this and how these two arenas have been addressed. The rise of increasingly drug resistant forms of tuberculosis has stimulated the development of new WHO and other guidelines addressing how to deal with this problem. The links between public health, ethics and legal mandate are presented, and the implications of this for controlling transmission of drug resistant disease, on the one hand, and the drive for greater patient support mechanisms on the other. Looking forwards to uncertain ethical and public health futures, these issues will be mediated by emergent WHO and international frameworks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721757     DOI: 10.1080/13648470.2010.493606

Source DB:  PubMed          Journal:  Anthropol Med        ISSN: 1364-8470


  13 in total

1.  Children's roles in tuberculosis treatment regimes: constructing childhood and kinship in urban Zambia.

Authors:  Jean Hunleth
Journal:  Med Anthropol Q       Date:  2013-06-26

2.  The political and ethical challenge of multi-drug resistant tuberculosis.

Authors:  Chris Degeling; Christopher Mayes; Wendy Lipworth; Ian Kerridge; Ross Upshur
Journal:  J Bioeth Inq       Date:  2015-01-29       Impact factor: 1.352

3.  The Global in Global Health is Not a Given.

Authors:  Paul H Mason; Ian Kerridge; Wendy Lipworth
Journal:  Am J Trop Med Hyg       Date:  2017-01-30       Impact factor: 2.345

4.  Surveillance or support: The experience of direct observation during tuberculosis treatment.

Authors:  Ietza Bojorquez; Irais Salazar; Richard S Garfein; Paris Cerecer; Timothy C Rodwell
Journal:  Glob Public Health       Date:  2016-10-16

5.  Determinants of Medication Adherence for Pulmonary Tuberculosis Patients During Continuation Phase in Dalian, Northeast China.

Authors:  Liang Du; Xu Chen; Xuexue Zhu; Yu Zhang; Ruiheng Wu; Jia Xu; Haoqiang Ji; Ling Zhou; Xiwei Lu
Journal:  Patient Prefer Adherence       Date:  2020-07-07       Impact factor: 2.711

6.  Negotiating "The Social" and Managing Tuberculosis in Georgia.

Authors:  Erin Koch
Journal:  J Bioeth Inq       Date:  2016-01-06       Impact factor: 1.352

7.  Bridging the gap between policy and practice: a qualitative analysis of providers' field experiences tinkering with directly observed therapy in patients with drug-resistant tuberculosis in Addis Ababa, Ethiopia.

Authors:  Kirubel Manyazewal Mussie; Christoph Gradmann; Tsegahun Manyazewal
Journal:  BMJ Open       Date:  2020-06-16       Impact factor: 2.692

8.  Point-of-Care Blood Tests: Do Indian Villagers Have Cultural Objections?

Authors:  Marika Vicziany; Jaideep Hardikar
Journal:  Front Chem       Date:  2018-11-06       Impact factor: 5.221

9.  Towards an empowerment approach in tuberculosis treatment in Cape Town, South Africa: a qualitative analysis of programmatic change.

Authors:  Salla Atkins; Simon Lewin; Karin C Ringsberg; Anna Thorson
Journal:  Glob Health Action       Date:  2012-08-16       Impact factor: 2.640

10.  Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation.

Authors:  Victoria A Wade; Jonathan Karnon; Jaklin A Eliott; Janet E Hiller
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.